semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed ductal carcinoma in situ (DCIS*) or invasive* adenocarcinoma of the breast Stage 0, I, or II disease Stage II tumors must be ≤ 3 cm Gross disease must be unifocal Microscopic multifocality allowed provided total pathological tumor size is ≤ 3 cm No proven multicentric carcinoma in more than 1 quadrant or separated by ≥ 4 cm No non-epithelial breast malignancies (e.g., sarcoma or lymphoma) NOTE: *Patients who are 50 years of age and over with DCIS regardless of hormone receptor status AND patients with invasive breast cancer meeting all of the following ≥ 50 years of age, node-negative, and hormone-receptor positive status will not be enrolled in study after 12/30/2006 Prior axillary staging required for patients with invasive breast cancer, including 1 of the following Sentinel node biopsy alone (if sentinel node is negative) Sentinel node biopsy followed by axillary dissection or sampling with ≥ 6 axillary nodes (if sentinel node is positive)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Neoplasm Metastasis Histological or cytological diagnoses of breast cancer, with metastases Metastatic lesions should not be curable with surgery or radiotherapy Women of age > 18 To have received a previous treatment with anthracyclines and taxanes A maximum of 2 previous chemotherapy treatment lines for metastatic disease Previous radiotherapy is allowed, whenever the radiated area is not the only disease location At least 4 weeks since the last previous antineoplastic treatment; patient must have recovered from all previous toxicities Performance status < 2 in World Health Organization (WHO) scale Clinically measurable, non measurable or really non measurable disease, as per Response Evaluation in Solid Tumors (RECIST) criteria Life expectancy of at least 12 weeks  Active infection or serious concomitant disease (investigator's criteria) Clinical evidence of metastases in the central nervous system (CNS) Blastic bone lesions as only disease Previous neurological toxicity grade 3-4 National Cancer Institute (NCI) Common Toxicity (CTC) v.2.0 Previous treatment with gemcitabine and/or vinorelbine More than 2 previous chemotherapy treatment lines for metastatic disease Abnormal liver function (bilirubin > 2.0-fold upper normal limit (UNL); alanine transaminase (ALT) and aspartate transaminase (AST) >2.5-fold UNL). In patients with hepatic metastasis, a value of ALT and AST of up to 5-fold UNL is permitted Unpaired renal function (creatinine > 2.0 mg/dL) Pregnancy or lactating Treatment with any investigational agent in the previous 4 weeks
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Cancer of the Breast Clinically node negative operable breast cancer No prior incision or excision biopsy  Palpable axillary lymph nodes Contraindications for injecting radiocolloid
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Neoplasm Metastasis Written informed consent Age >= 18 years old Metastatic breast cancer patients with lytic, sclerotic or mixed bone lesions Non-symptomatic bone lesions, defined as pain absence, lack of bone complications (fracture, hypercalcemia, Central Nervous System (CNS) compression), no need of analgesic chronic administration for bone disease A maximum of two chemotherapy lines for metastatic disease A maximum of two hormone therapy lines for metastatic disease Normal, minimally altered renal function (serum creatinine < 1.5 x Upper Normal Limit (UNL)) Normal serum calcium levels Performance status 0,1 (World Health Organization (WHO)) Negative pregnancy test before study recruitment  Previous treatment with bisphosphonates or raloxifene in the 30 days prior to randomization Metastasis in CNS History of hypersensitivity to bisphosphonates Pregnant or lactating women Third chemotherapy line for metastatic disease Third hormone therapy line for metastatic disease Males
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-70.0,  Breast Cancer Written informed consent Women older than 18 years old HER2 positive breast cancer with histological diagnoses Non-operable locally advanced or metastatic disease, previously treated with trastuzumab and taxanes Measurable or non-measurable disease as per Response Evaluation in Solid Tumors (RECIST) Disease progression during or after treatment with trastuzumab and taxanes Maximum of 1 previous chemotherapy line for advanced or metastatic disease Previous radiotherapy is allowed if radiated area is not the only documented lesion At least 4 weeks since the last administration of antineoplastic treatment and all toxicities resolved Performance status Eastern Cooperative Oncology Group (ECOG) >=2  History of hypersensitivity to vinorelbine, trastuzumab, rat proteins or trastuzumab components History of dyspnea at rest, or chronic oxygen therapy required Active infection Second malignancy, except for cervical in situ carcinoma, basal skin carcinoma, adequately treated. Previous malignancies with a 5 year disease free survival are allowed Pregnant or lactating women Any other serious medical pathology, such as congestive heart failure, unstable angina, history of myocardial infarction during the previous year, uncontrolled hypertension or high risk arrhythmias History of neurological or psychiatric disorders, which could preclude the patients to free informed consent Active uncontrolled infection Active peptic ulcer, unstable diabetes mellitus Concomitant treatment with other investigational products. Participation in other clinical trials with a non-marketed drug in the 30 previous days before randomization
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Female patient, postmenopausal, defined as a woman fulfilling any one of the following Age 60 years or older Age 45 years or older with amenorrhea for > 12 months with an intact uterus Follicle-stimulating hormone and estradiol levels within post-menopausal range Having undergone a bilateral oophorectomy Histologically or cytologically proven adenocarcinoma of the breast Subjects must have archived rumor tissue available to compare the clinical response with tumor expression of biomarkers, such as HER-2, ER and PR; archived tissue will be used to confirm HER-2, ER and PR status, but results will not be used to determine subject for the study HER2-positive disease ER-positive and/or PR-positive disease ECOG performance status 0-2  Prior chemotherapy, hormonal therapy, Herceptin or other investigational therapy for metastatic breast cancer Prior treatment with Faslodex Concurrent therapy with any other non-protocol anti-cancer therapy Current or prior history of brain metastases History of any other malignancy within the past 5 years, with the exception of non-melanoma skin cancer or carcinoma-in-situ of the cervix Clinically significant cardiovascular disease, New York Heart Association Class II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication Prior exposure of > 360 mg/m2 doxorubicin or liposomal doxorubicin, > 120 mg/m2 mitoxantrone, > 90 mg/m2 idarubicin, or > 720 mg/m2 epirubicin Active, uncontrolled infection requiring parenteral antimicrobials The presence of any other medical or psychiatric disorder that, in the opinion of the treating physician, would contraindicate the use of the drugs in this protocol or place the subject at undue risk for treatment complications Inability to comply with the study protocol or follow-up procedures
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HER-2 Positive Metastatic Breast Cancer Patients with biopsy proven, measurable metastatic breast cancer. Patients with bone-only, and/or effusion-only disease are excluded HER-2 neu positive by standard immunohistochemical (2+ positivity) No prior chemotherapy for distant metastatic disease Prior paclitaxel in the adjuvant setting is allowed Karnofsky performance status equal to 70 or greater ANC > 1500, Hgb > 10, plt > 100 Patients with some degree of hepatic dysfunction and renal dysfunction are encouraged, in order to evaluate the ability of the ERMBT in tailoring dose in these patient populations  Age less than 18 years Allergy to erythromycin Previous treatment with docetaxel. Prior paclitaxel is allowed Grade > 2 peripheral neuropathy No confounding factors present to provide misinterpretation of data (i.e., concurrent malignancy) Patients who are pregnant or nursing will not be eligible for this protocol. Women of childbearing age who are not practicing reliable birth control must have a documented negative serum HCG Patients who require concurrent treatment with drugs which are known to induce or inhibit CYP3A activity will be ineligible for the trial. This list includes the drugs midazolam, anti-mycotic agents (ketoconazole and related compounds), macrolide antibiotics (erythromycin and related compounds), nifedipine, anti-seizure drugs, and rifampin (induction)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-85.0,  Cervical Cancer cervical cancer patients receiving radiotherapy or chemo-radiotherapy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 40.0-999.0,  Breast Cancer Carcinoma, Ductal Women >= 40 with invasive ductal carcinoma or ductal carcinoma in situ 2. Patient chooses lumpectomy rather than mastectomy as treatment for breast cancer 3. Tumor < 2.5 cm in size, 2 mm margin of normal breast tissue between cancer and edge of specimen  Men 2. Prior malignancy, breast or other if metastatic or with anticipated survival of < 5 years 3. Pregnant women 4. Immunocompromised 5. Poorly controlled insulin dependent diabetes 6. Contraindication to radiotherapy, e.g. connective tissue disorder such as scleroderma 7. Breast cancer that involves skin or chest wall 8. Multifocal or Multicentric breast cancer 9. Invasive lobular carcinoma 10. Diffuse microcalcifications on mammography 11. Invasive carcinoma with extensive intraductal component (EIC) 12. Greater than 12 weeks since definitive surgical excision or completion of chemotherapy 13. Involved lymph nodes detected by frozen section or touch preparation at time of lumpectomy 14. Patients with 1 to 3 positive lymph nodes determined postoperatively (does not patients with micro-metastases) 15. Subglandular or submuscular breast implants (does not patients having implants placed AFTER intra-operative radiotherapy)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Neoplasms Anemia Age ≥ 18 years Well-informed written consent, signed by the patient Patient picked up for solid tumor treatment, whichever the localization, with or without metastasis Patient revealing, before or during chemotherapy, a moderate anemia, that means: Men: 9<Hb<12 g/dl; Women: 9<Hb<11 g/dl Patient for who at least four chemotherapy cycles are planed (eight in case of weekly chemotherapy) after in the study Patients with life expectancy higher than three months Patient with general conditions compatible with the study's follow-up  Contra-indication for Venofer Anemia which can have curative treatment Bloody transfusion during the previous four weeks Documented or suspected medullary invasion Uncontrolled arterial hypertension Acute bacterial infection Transferrin saturation's coefficient Pregnancy Ferric salts oral treatment interrupted since less than one week Patient with bad french language's comprehension
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Invasive breast cancer or DCIS, tumor stage of Tis, T1, T2 if lesion is < 3 cm, N0 or N1 if 1-3 + nodes with no extracapsular extension
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Breast Cancer Histologically confirmed invasive breast cancer by fine needle aspiration or biopsy Locally advanced or early metastatic disease Clinically or radiographically measurable disease Planning to receive neoadjuvant chemotherapy for locally advanced or early metastatic disease Hormone receptor status Not specified Age Not specified Sex Not specified Menopausal status Not specified Performance status Not specified Life expectancy
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Histologically confirmed advanced or metastatic breast cancer postmenopausal females with amenorrhoea > 12 months and an intact uterus FSH levels within postmenopausal range or have undergone a bilateral oophorectomy ER &/or PR positive previous adjuvant hormone therapy > 12 months prior to enrolment previous adjuvant chemotherapy > 6 months prior to enrolment measurable disease according to and/or non measurable bone disease life expectancy of at least 12 weeks World Health Organisation (WHO) performance status (PS) of 0 to 1  Male life-threatening metastatic visceral disease evidence of clinically active interstitial lung disease ER and PR negative treatment with LHRH analogues < 3 months prior to enrolment patients who have restarted menses or do not have FSH levels within the postmenopausal range treatment with strontium (or other radio pharmaceutical) within the previous 3 months Treatment with hormonotherapy and/or chemotherapy for advanced disease extensive radiotherapy to measurable lesions within the last 4 weeks (i.e. >30% of bone marrow, e.g. whole of pelvis or half of spine)
Patient description: The patient is a 45-year-old postmenopausal woman with cytologically confirmed breast cancer. A core biopsy revealed a 3 cm invasive ductal breast carcinoma in the left upper outer quadrant. The tumor is HER2-positive and ER/PR negative. Axillary sampling revealed 5 positive lymph nodes. CXR was remarkable for metastatic lesions. The patient is using multivitamins and iron supplements. She does not smoke or consume alcohol. She is not sexually active and has no children. She is a candidate for tumor resection and agrees to do so prior to chemotherapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Breast Cancer Signed informed consent, premenopausal women 18 years or older, histologically or cytologically confirmed locally advanced or metastatic breast cancer, suitable for endocrine treatment, no curative treatment available,, one or more measurable lesions, life expectancy more than 6 months, normal biological parameters  Presence of life-threatening metastases, previous endocrine therapy or chemotherapy for advanced or metastatic disease, any previous treatment with hormone (LH-RH) severe or uncontrolled systemic disease, pituitary adenoma, High risk of medullar compression